Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor

Journal of Immunology

Volumn 171, Issue 5, 2003, Pages 2374-2383

  Hornell, Tara M C ^a,c   Beresford, Guy W ^b   Bushey, Alyssa ^b   Boss, Jeremy M ^b   Mellins, Elizabeth D ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RNA; T6 ANTIGEN;

ARTICLE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOPOTENTIATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MIXED LYMPHOCYTE REACTION; MONOCYTE;

EID: 0041929516     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.171.5.2374     Document Type: Article

References (57)

1. Muller, W. A. 2001. New mechanisms and pathways for monocyte recruitment. J. Exp. Med. 194:F47.
2. Fleischer, J., E. Soeth, N. Reiling, E. Grage-Griebenow, H. D. Flad, and M. Ernst. 1996. Differential expression and function of CD80 (B7-1) and CD86 (B7-2) on human peripheral blood monocytes. Immunology 89:592.
3. Laupeze, B., O. Fardel, M. Onno, N. Bertho, B. Drenou, R. Fauchet, and L. Amiot. 1999. Differential expression of major histocompatibility complex class Ia, Ib, and II molecules on monocytes-derived dendritic and macrophagic cells. Hum. Immunol. 60:591.
4. Busch, R., and E. D. Mellins. 1996. Developing and shedding inhibitions: how MHC class II molecules reach maturity. Curr. Opin. Immunol. 8:51.
5. Liljedahl, M., T. Kuwana, W. P. Fung-Leung, M. R. Jackson, P. A. Peterson, and L. Karlsson. 1996. HLA-DO is a lysosomal resident which requires association with HLA-DM for efficient intracellular transport. EMBO J. 15:4817.
6. Denzin, L. K., D. B. Sant'Angelo, C. Hammond, M. J. Surman, and P. Cresswell. 1997. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 278:106.
7. Van Ham, S. M., E. P. Tjin, B. F. Lillemeier, U. Gruneberg, K. E. van Meijgaarden, L. Pastoors, D. Verwoerd, A. Tulp, B. Canas, D. Rahman, et al. 1997. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading. Curr. Biol. 7:950.
8. Karlsson, L., C. D. Surh, J. Sprent, and P. A. Peterson. 1991. A novel class II MHC molecule with unusual tissue distribution. Nature 351:485.
9. Tonnelle, C., R. DeMars, and E. O. Long. 1985. DOβ: a new β chain gene in HLA-D with a distinct regulation of expression. EMBO J. 4:2839.
10. Surh, C. D., E. K. Gao, H. Kosaka, D. Lo, C. Ahn, D. B. Murphy, L. Karlsson, P. Peterson, and J. Sprent. 1992. Two subsets of epithelial cells in the thymic medulla. J. Exp. Med. 176:495.
11. Douek, D. C., and D. M. Altmann. 1997. HLA-DO is an intracellular class II molecule with distinctive thymic expression. Int. Immunol. 9:355.
12. Chen, X., O. Laur, T. Kambayashi, S. Li, R. A. Bray, D. A. Weber, L. Karlsson, and P. E. Jensen. 2002. Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. J. Exp. Med. 195:1053.
13. Reith, W., and B. Mach. 2001. The bare lymphocyte syndrome and the regulation of MHC expression. Annu. Rev. Immunol. 19:331.
14. Muhlethaler-Mottet, A., L. A. Otten, V. Steimle, and B. Mach. 1997. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16:2851.
15. Piskurich, J. F., Y. Wang, M. W. Linhoff, L. C. White, and J. P. Ting. 1998. Identification of distinct regions of 5′ flanking DNA that mediate constitutive, IFN-γ, STAT1, and TGF-β-regulated expression of the class II transactivator gene. J. Immunol. 160:233.
16. Nicola, N. A. 2000. GM-CSF. In Cytokine Reference. J. J. Oppenheim and M. Feldmann, eds. Academic Press, London, p. 899.
17. Hamilton, J. A. 2002. GM-CSF in inflammation and autoimmunity. Trends Immunol. 23:403.
18. Mach, N., and G. Dranoff. 2000. Cytokine-secreting tumor cell vaccines. Curr. Opin. Immunol. 12:571.
19. Jones, T. C. 1999. Use of granulocyte-macrophage colony stimulating factor (GM-CSF) in prevention and treatment of fungal infections. Eur. J. Cancer. 35 (Suppl. 3):S8.
20. Bertho, N., B. Drenou, B. Laupeze, C. L. Berre, L. Amiot, J. M. Grosset, O. Fardel, D. Charron, N. Mooney, and R. Fauchet. 2000. HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC. J. Immunol. 164:2379.
21. Lampson, L. A., and R. Levy. 1980. Two populations of Ia-like molecules on a human B cell line. J. Immunol. 125:293.
22. Beresford, G. W., and J. M. Boss. 2001. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. Nat. Immun. 2:652.
23. Sette, A., S. Southwood, J. Miller, and E. Appella. 1995. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allclic polymorphism in class II. J. Exp. Med. 181:677.
24. Stebbins, C. C., G. E. Loss, Jr., C. G. Elias, A. Chervonsky, and A. J. Sant. 1995. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J. Exp. Med. 181:223.
25. Elliott, E. A., J. R. Drake, S. Amigorena, J. Elsemore, P. Webster, I. Mellman and R. A. Flavell. 1994. The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J. Exp. Med. 179:681.
26. Taxman, D. J., D. E. Cressman, and J. P. Ting. 2000. Identification of class II transcriptional activator-induced genes by representational difference analysis: discoordinate regulation of the DNα/DOβ heterodimer. J. Immunol. 165:1410.
27. Munder, M., M. Mallo, K. Eichmann, and M. Modolell. 1998. Murine macrophages secrete interferon γ upon combined stimulation with interleukin (IL)-12 and IL-18: a novel pathway of autocrine macrophage activation. J. Exp. Med. 187:2103.
28. Koppelman, B., J. J. Neefjes, J. E. de Vries, and R. de Waal Malefyt. 1997. Interleukin-10 down-regulates MHC class II αβ peptide complexes at the plasma membrane of monocytes by affecting arrival and recycling. Immunity 7:861.
29. Ting, J. P., and J. Trowsdale. 2002. Genetic control of MHC class II expression. Cell 109:S21.
30. Nagarajan, U. M., J. Lochamy, X. Chen, G. W. Beresford, R. Nilsen, P. E. Jensen, and J. M. Boss. 2002. Class II transactivator is required for maximal expression of HLA-DOB in B cells. J. Immunol. 168:1780.
31. Nickerson, K., T. J. Sisk, N. Inohara, C. S. Yec, J. Kennell, M. C. Cho, P. J. Yannie II, G. Nunez, and C. H. Chang. 2001. Dendritic cell-specific MHC class II transactivator contains a caspase recruitment domain that confers potent transactivation activity. J. Biol. Chem. 276:19089.
32. O'Keefe, G. M., V. T. Nguyen, L. L. Ping Tang, and E. N. Benveniste. 2001. IFN-γ regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein. J. Immunol. 166:2260.
33. Soos, J. M., J. Morrow, T. A. Ashley, B. E. Szente, E. K. Bikoff, and S. S. Zamvil. 1998. Astrocytes express elements of the class II endocytic pathway and process central nervous system autoantigen for presentation to encephalitogenic T cells. J. Immunol. 161:5959.
34. Waldburger, J. M., T. Suter, A. Fontana, H. Acha-Orbea, and W. Reith. 2001. Selective abrogation of major hik6compatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene. J. Exp. Med. 194:393.
35. Holling, T. M., N. van der Stoep, E. Quinten, and P. J. van den Elsen. 2002. Activated human T cells accomplish MHC class II expression through T cell-specific occupation of class II transactivator promoter III. J. Immunol. 168:763.
36. Wong, A. W., N. Ghosh, K. P. McKinnon, W. Reed, J. F. Piskurich, K. L. Wright, and J. P. Ting. 2002. Regulation and specificity of MHC2TA promoter usage in human primary T lymphocytes and cell line. J. Immunol. 169:3112.
37. Landmann, S., A. Muhlethaler-Mottet, L. Bemasconi, T. Suter, J. M. Waldburger, K. Masternak, J. F. Arrighi, C. Hauser, A. Fontana, and W. Reith. 2001. Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression. J. Exp. Med. 194:379.
38. Pai, R. K., D. Askew, W. H. Boom, and C. V. Harding. 2002. Regulation of class II MHC expression in APCs: roles of types I, III, anct IV class II transactivator. J. Immunol. 169:1326.
39. Ghosh, N., J. F. Piskurich, G. Wright, K. Hassani, J. P. Ting, and K. L. Wright. 1999. A novel element and a TEF-2-like element activate the major histocompatibility complex class II transacfivator in B-lymphocytes. J. Biol. Chem. 274:32342.
40. Piskurich, J. F., M. W. Linhoff, Y. Wang, and J. P. Ting. 1999. Two distinct γ interferon-inducible promoters of the major histocompatibility complex class II transactivator gene are differentially regulated by STAT1, interferon regulatory factor 1, and transforming growth factor β. Mol. Cell. Biol. 19:431.
41. Quelle, F. W., N. Sato, B. A. Witthuhn, R. C. Inhorn, M. Eder, A. Miyajima, J. D. Griffin, and J. N. Ihle. 1994. JAK2 associates with the βc chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol. Cell. Biol. 14:4335.
42. Mui, A. L., H. Wakao, A. M. O'Farrell, N. Harada, and A. Miyajima. 1995. Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J. 14:1166.
43. Brizzi, M. F., M. G. Aronica, A. Rosso, G. P. Bagnara, Y. Yarden, and L. Pegoraro. 1996. Granulocyte-macrophage colony-stimulating factor stimulates JAK2 signaling pathway and rapidly activates p93fes, STAT1 p91, and STAT3 p92 in polymorphonuclear leukocytes. J. Biol. Chem. 271:3562.
44. Welte, T., F. Koch, G. Schuler, J. Lechner, W. Doppler, and C. Heufler. 1997. Granulocyte-macrophage colony-stimulating factor induces a unique set of STAT factors in murine dendritic cells. Eur. J. Immunol. 27:2737.
45. Shibata, Y., P. Y. Berclaz, Z. C. Chroneos, M. Yoshida, J. A. Whitsett, and B. C. Trapnell. 2001. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 15:557.
46. Li, J., A. I. Colovai, R. Cortesini, and N. Suciu-Foca. 2000. Cloning and functional characterization of the 5'-regulatory region of the human CD86 gene. Hum. Immunol. 61:486.
47. Nguyen, V. T., and E. N. Benveniste. 2000. Involvement of STAT-1 and ets family members in interferon-γ induction of CD40 transcription in microglia/ macrophages. J. Biol. Chem. 275:23674.
48. Brissette, W. H., D. A. Baker, E. J. Stam, J. P. Umland, and R. J. Griffiths. 1995. GM-CSF rapidly primes mice for enhanced cytokine production in response to LPS and TNF. Cytokine 7:291.
49. Re, F., S. L. Belyanskaya, R. J. Riese, B. Cipriani, F. R. Fischer, F. Granucci, P. Ricciardi-Castagnoli, C. Brosnan, L. J. Stem, J. L. Strominger, and L. Santambrogio. 2002. Granulocyte-macrophage colony-stimulating factor induces an expression program in neonatal microglia that primes them for antigen presentation. J. Immunol. 169:2264.
50. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22:633.
51. Xu, W. D., G. S. Firestein, R. Taetle, K. Kaushansky, and N. J. Zvaifler. 1989. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J. Clin. Invest. 83:876.
52. De Vries, E. G., P. H. Willemse, B. Biesma, A. C. Stern, P. C. Limburg, and E. Vellenga. 1991. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet 338:517.
53. Hansen, P. B., H. E. Johnsen, and E. Hippe. 1993. Autoimmune hypothyroidism and granulocyte-macrophage colony-stimulating factor. Eur. J. Haematol. 50:183.
54. Hoekman, K., B. M. von Blomberg-van der Flier, J. Wagstaff, H. A. Drexhage, and H. M. Pinedo. 1991. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 338:541.
55. Biondo, M., Z. Nasa, A. Marshall, B. H. Toh, and F. Alderuccio. 2001. Local transgenic expression of granulocyte macrophage-colony stimulating factor initiates autoimmunity. J. Immunol. 166:2090.
56. Campbell, I. K., A. Bendele, D. A. Smith, and J. A. Hamilton. 1997. Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann. Rheum. Dis. 56:364.
57. Cook, A. D., E. L. Braine, I. K. Campbell, M. J. Rich, and J. A. Hamilton. 2001. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 3:293.